CLGN and prostate adenocarcinoma: In addition, the mRNA expression of CLGN was high in breast invasive carcinoma, kidney chromophobe, kidney renal papillary cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma prostate adenocarcinoma, and uterine corpus endometrial carcinoma (p < 0.01, Figure 3).